Literature DB >> 10744186

Describing paraspinal EMG findings: inadequacy of the single 0-4+ score.

A J Haig1, J W Levine, C Ruan, K Yamakawa.   

Abstract

OBJECTIVE: Clinical electrodiagnostic textbooks instruct that lumbar radiculopathies typically have paraspinal abnormalities and that these abnormalities should be recorded using a single 0-4+ scale. Recent work demonstrates that that the innervation of the paraspinal muscles is segmental, not homogenous, and that asymptomatic persons may have reproducible ("1+") positive waves or fibrillation potentials.
DESIGN: To assess current use of the 0-4+ scale, a retrospective study of EMG scores in persons diagnosed with radiculopathy at a university laboratory was performed. No specific paraspinal EMG technique was used. Included were 117 consecutive, qualified S-1 radiculopathies and 33 L-5 radiculopathies.
RESULTS: When radiculopathy was defined by "more than one limb muscle abnormal," paraspinal scores were recorded as 0 to 1+ in 83% of L-5 and 63% of S-1 cases (chi2, L-5 vs. S-1, not significant). For more severe radiculopathies (at least one limb muscle with a "2+" score), 0-1+ paraspinal scores were recorded in 76% of L-5 and 57% of S-1 cases (chi2, not significant). A total of 82% of S-1 radiculopathies with no overlapping L-5 innervation had 0-1+ scores.
CONCLUSIONS: These data demonstrate the common use of equivocal paraspinal scores in patients whom electromyographers believe have radiculopathies. Standardized exploration techniques and a more detailed scoring system for the paraspinal muscles may eliminate this discrepancy.

Entities:  

Mesh:

Year:  2000        PMID: 10744186     DOI: 10.1097/00002060-200003000-00004

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  1 in total

1.  Polysegmental innervation of the medial paraspinal lumbar muscles.

Authors:  Michael Kottlors; Franz Xaver Glocker
Journal:  Eur Spine J       Date:  2007-10-31       Impact factor: 3.134

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.